395 research outputs found

    Pyrolysis gas as a carbon source for biogas production via anaerobic digestion

    Get PDF
    Carbon is an important resource for anaerobes to enhance biogas production. In this study, the possibility of using simulated pyrolysis gas (SPG) as a carbon source for biogas production was investigated. The effects of stirring speed (SS), gas holding time (GHT), and H2 addition on biomethanation of SPG were evaluated. The diversity and structure of microbial communities were also analyzed under an illumina MiSeq platform. Results indicated that at a GHT of 14 h and an SS at 400 rpm, SPG with up to 64.7% CH4could be bio-upgraded to biogas. Gas–liquid mass transfer is the limitation for SPG biomethanation. For the first time, it has been noticed that the addition of H2 can bioupgrade SPG to high quality biogas (with 91.1% CH4). Methanobacterium was considered as a key factor in all reactors. This study provides an idea and alternative way to convert lignocellulosic biomass and solid organic waste into energy (e.g., pyrolysis was used as a pretreatment to produce pyrolysis gas from biomass, and then, pyrolysis gas was bioupgraded to higher quality biogas via anaerobic digestion)

    Universal Murray's law for optimised fluid transport in synthetic structures

    Full text link
    Materials following Murray's law are of significant interest due to their unique porous structure and optimal mass transfer ability. However, it is challenging to construct such biomimetic hierarchical channels with perfectly cylindrical pores in synthetic systems following the existing theory. Achieving superior mass transport capacity revealed by Murray's law in nanostructured materials has thus far remained out of reach. We propose a Universal Murray's law applicable to a wide range of hierarchical structures, shapes and generalised transfer processes. We experimentally demonstrate optimal flow of various fluids in hierarchically planar and tubular graphene aerogel structures to validate the proposed law. By adjusting the macroscopic pores in such aerogel-based gas sensors, we also show a significantly improved sensor response dynamic. Our work provides a solid framework for designing synthetic Murray materials with arbitrarily shaped channels for superior mass transfer capabilities, with future implications in catalysis, sensing and energy applications.Comment: 19 pages, 4 figure

    Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma

    Get PDF
    Limited studies have focused on developing prognostic models with trans-omics biomarkers for early-stage lung adenocarcinoma (LUAD). We performed integrative analysis of clinical information, DNA methylation, and gene expression data using 825 early-stage LUAD patients from 5 cohorts. Ranger algorithm was used to screen prognosis-associated biomarkers, which were confirmed with a validation phase. Clinical and biomarker information was fused using an iCluster plus algorithm, which significantly distinguished patients into high- and low-mortality risk groups (Pdiscovery = 0.01 and Pvalidation = 2.71×10-3). Further, potential functional DNA methylation-gene expression-overall survival pathways were evaluated by causal mediation analysis. The effect of DNA methylation level on LUAD survival was significantly mediated through gene expression level. By adding DNA methylation and gene expression biomarkers to a model of only clinical data, the AUCs of the trans-omics model improved by 18.3% (to 87.2%) and 16.4% (to 85.3%) in discovery and validation phases, respectively. Further, concordance index of the nomogram was 0.81 and 0.77 in discovery and validation phases, respectively. Based on systematic review of published literatures, our model was superior to all existing models for early-stage LUAD. In summary, our trans-omics model may help physicians accurately identify patients with high mortality risk

    SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic-smoking interaction analysis

    Get PDF
    Smoking cessation prolongs survival and decreases mortality of patients with non‐small‐cell lung cancer (NSCLC). In addition, epigenetic alterations of some genes are associated with survival. However, potential interactions between smoking cessation and epigenetics have not been assessed. Here, we conducted an epigenome‐wide interaction analysis between DNA methylation and smoking cessation on NSCLC survival. We used a two‐stage study design to identify DNA methylation-smoking cessation interactions that affect overall survival for early‐stage NSCLC. The discovery phase contained NSCLC patients from Harvard, Spain, Norway, and Sweden. A histology‐stratified Cox proportional hazards model adjusted for age, sex, clinical stage, and study center was used to test DNA methylation-smoking cessation interaction terms. Interactions with false discovery rate‐q ≤ 0.05 were further confirmed in a validation phase using The Cancer Genome Atlas database. Histology‐specific interactions were identified by stratification analysis in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. We identified one CpG probe (cg02268510SIPA1L3) that significantly and exclusively modified the effect of smoking cessation on survival in LUAD patients [hazard ratio (HR)interaction = 1.12; 95% confidence interval (CI): 1.07-1.16; P = 4.30 × 10-7]. Further, the effect of smoking cessation on early‐stage LUAD survival varied across patients with different methylation levels of cg02268510SIPA1L3. Smoking cessation only benefited LUAD patients with low methylation (HR = 0.53; 95% CI: 0.34-0.82; P = 4.61 × 10-3) rather than medium or high methylation (HR = 1.21; 95% CI: 0.86-1.70; P = 0.266) of cg02268510SIPA1L3. Moreover, there was an antagonistic interaction between elevated methylation of cg02268510SIPA1L3 and smoking cessation (HRinteraction = 2.1835; 95% CI: 1.27-3.74; P = 4.46 × 10−3). In summary, smoking cessation benefited survival of LUAD patients with low methylation at cg02268510SIPA1L3. The results have implications for not only smoking cessation after diagnosis, but also possible methylation‐specific drug targeting
    corecore